Meropenem sodium salt | CAS# 211238-34-5 | Antibiotic

MedKoo Cat#: 574478 | Name: Meropenem sodium salt

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Meropenem sodium salt is a carbapenem antibiotic.

Chemical Structure

Meropenem sodium salt

CAS#211238-34-5 (sodium)

Theoretical Analysis

MedKoo Cat#: 574478

Name: Meropenem sodium salt

CAS#: 211238-34-5 (sodium)

Chemical Formula: C17H24N3NaO5S

Exact Mass: 405.1334

Molecular Weight: 405.44

Elemental Analysis: C, 50.36; H, 5.97; N, 10.36; Na, 5.67; O, 19.73; S, 7.91

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

96036-03-2 (free) 119478-56-7 (hydrate) 211238-34-5 (sodium)

Synonym

Meropenem sodium salt

IUPAC/Chemical Name

sodium 3-((5-(dimethylcarbamoyl)pyrrolidin-3-yl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

InChi Key

UBQRNADYCUXRBD-UHFFFAOYSA-M

InChi Code

InChI=1S/C17H25N3O5S.Na/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);/q;+1/p-1

SMILES Code

CC1C2C(C(=O)N2C(=C1SC3CC(NC3)C(=O)N(C)C)C(=O)[O-])C(C)O.[Na+]

Appearance

Light Yellow Solid

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Meropenem sodium salt is a carbapenem antibiotic.

In vitro activity:

Meropenem, a new parenteral carbapenem demonstrated increased activity as compared to imipenem against 336 strains of Neisseria gonorrhoeae, 119 strains of Haemophilus influenzae, and 110 strains of H. ducreyi. Reference: J Antimicrob Chemother. 1989 Sep;24 Suppl A:183-6. https://pubmed.ncbi.nlm.nih.gov/2509415/

In vivo activity:

Group 3 was injected with meropenem 60 mg/kg/d i.p, group 4 with deferoxamine 80 mg/kg/d s.c and group 5 with combination of these 2 agents at the same doses. While meropenem was started 2 hours later, all treatments were started immediately after the induction of pancreatitis. All rats were killed at the 48th hour of the treatment and blood and tissue samples were collected for amylase determinations, pathologic examinations, and culture. Meropenem significantly reduced the incidence of pancreatic infection. Reference: Pancreas. 2003 Oct;27(3):247-52. https://pubmed.ncbi.nlm.nih.gov/14508131/

Preparing Stock Solutions

The following data is based on the product molecular weight 405.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Slaney L, Chubb H, Mohammed Z, Ronald A. In-vitro activity of meropenem against Neisseria gonorrhoeae, Haemophilus influenzae and H. ducreyi from Canada and Kenya. J Antimicrob Chemother. 1989 Sep;24 Suppl A:183-6. doi: 10.1093/jac/24.suppl_a.183. PMID: 2509415. 2. Jones RN, Barry AL, Thornsberry C. In-vitro studies of meropenem. J Antimicrob Chemother. 1989 Sep;24 Suppl A:9-29. doi: 10.1093/jac/24.suppl_a.9. PMID: 2808218. 3. Wang Y, Liu L, Wu Q, Yin Q, Xie F. Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model. Antibiotics (Basel). 2022 Nov 19;11(11):1660. doi: 10.3390/antibiotics11111660. PMID: 36421304; PMCID: PMC9686672. 4. Ateskan U, Mas MR, Yasar M, Deveci S, Babaoglu E, Comert B, Mas NN, Doruk H, Tasci I, Ozkomur ME, Kocar IH. Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. Pancreas. 2003 Oct;27(3):247-52. doi: 10.1097/00006676-200310000-00010. PMID: 14508131.

In vitro protocol:

In vivo protocol:

1. Wang Y, Liu L, Wu Q, Yin Q, Xie F. Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model. Antibiotics (Basel). 2022 Nov 19;11(11):1660. doi: 10.3390/antibiotics11111660. PMID: 36421304; PMCID: PMC9686672. 2. Ateskan U, Mas MR, Yasar M, Deveci S, Babaoglu E, Comert B, Mas NN, Doruk H, Tasci I, Ozkomur ME, Kocar IH. Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. Pancreas. 2003 Oct;27(3):247-52. doi: 10.1097/00006676-200310000-00010. PMID: 14508131.